A.R.T. Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

A.R.T. Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,843	Closed	-$72K	–	1830
2019 Q3	$72K	Buy	6,843 +1,409	+26%	+$18.4K	﹤0.01%	1290
2019 Q2	$92K	Buy	5,434 +3,910	+257%	+$106K	0.01%	1206
2019 Q1	$51K	Buy	1,524 +62	+4%	+$2.07K	﹤0.01%	1215
2018 Q4	$43K	Sell	1,462 -1,321	-47%	-$58.6K	﹤0.01%	1226
2018 Q3	$171K	Buy	+2,783	New	+$188K	0.01%	1218
2018 Q2	–	Sell	-8,801	Closed	-$577K	–	1850
2018 Q1	$577K	Buy	+8,801	New	+$665K	0.02%	892
2016 Q1	–	Sell	-4,288	Closed	-$869K	–	1728
2015 Q4	$869K	Buy	4,288 +2,560	+148%	+$458K	0.04%	634
2015 Q3	$251K	Buy	+1,728	New	+$317K	0.01%	1097

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's BLCM Position: Q4 2019 in Review

A.R.T. Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2019, closing a stake of 6,843 shares — an estimated $72K sold.

A.R.T. Advisors first reported a position in BLCM in Q3 2015 and held it in 8 quarters. The position peaked at $869K in Q4 2015. 51 funds tracked by Wall St. Rank hold BLCM as of Q4 2019.

A.R.T. Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 6,843 Bellicum Pharmaceuticals, Inc. shares in Q4 2019, an estimated $72K.
A.R.T. Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 8 quarters.
A.R.T. Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $869K in Q4 2015.
51 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.